Oncolys BioPharma’s Telomere-Long product has been approved for handling as a pharmaceutical in medical insurance by the Central Social Insurance Medical Council, and sales are scheduled to begin from the 2026 fiscal year ending December.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-06-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4588-20260624-01.pdf","jir_short_summary":"Oncolys BioPharma's Telomere-Long product has been approved for handling as a pharmaceutical in medical insurance by the Central Social Insurance Medical Council, and sales are scheduled to begin from the 2026 fiscal year ending December.","jir_summary":"### Overview of Business Performance\nThis document does not provide financial results for Oncolys BioPharma but is an announcement regarding the handling of the Telomere-Long regenerative medicine product in medical insurance. The product received manufacturing and marketing approval on June 8, 2026, and was approved for handling as a pharmaceutical by the Central Social Insurance Medical Council. It is planned to be listed in the drug price standard after deliberations, with sales scheduled to commence from the 2026 fiscal year ending December. There is no impact on our financial results due to this matter.\n\n### Future Outlook and Impact on Shareholders\nWith this approval, the handling of Telomere-Long in medical insurance is confirmed, and preparations for sales are underway. Revenue from sales is expected to start from the 2026 fiscal year ending December, which could influence future business development and earnings forecasts. While there is no direct impact on our financial results, attention should be paid to upcoming sales developments and revenue realization.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#OncolysBioPharma, #IRRelated, #JapanStocks","jir_key_figures":"Scheduled sales start: from the 2026 fiscal year ending December\nApproval date: June 8, 2026\nImpact on financial results: None","jir_meta_title":"\u3010Oncolys BioPharma\u3011Approval of Medical Insurance Handling\uff5cJune 2026","jir_meta_description":"Oncolys BioPharma's Telomere-Long handling in medical insurance has been approved, with sales scheduled to start from the 2026 fiscal year ending December. No impact on financial results.","jir_og_title":"\u3010Oncolys BioPharma\u3011Approval of Medical Insurance Handling\uff5cJune 2026","jir_og_description":"Oncolys BioPharma's Telomere-Long handling in medical insurance has been approved, with sales scheduled to start from the 2026 fiscal year ending December. No impact on financial results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-68441","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n